Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 3/2015

01-06-2015 | Original Article

Effect on HPV vaccination in Japan resulting from news report of adverse events and suspension of governmental recommendation for HPV vaccination

Authors: Akiko Morimoto, Yutaka Ueda, Tomomi Egawa-Takata, Asami Yagi, Yoshito Terai, Masahide Ohmichi, Tomoyuki Ichimura, Toshiyuki Sumi, Hiromi Murata, Hideharu Kanzaki, Hidekatsu Nakai, Masaki Mandai, Kiyoshi Yoshino, Masami Fujita, Tadashi Kimura, Junko Saito, Tomotaka Sobue, Nobumichi Nishikawa, Masayuki Sekine, Takayuki Enomoto, Yorihiko Horikoshi, Tetsu Takagi

Published in: International Journal of Clinical Oncology | Issue 3/2015

Login to get access

Abstract

Background

Administration of the human papillomavirus (HPV) vaccine decreased dramatically in Japan after extensive news of adverse vaccine events and suspension of the governmental recommendation for the vaccine. In this study, we investigated the knowledge and acceptance of vaccinated adolescents concerning cervical cancer, cancer screening and the HPV vaccine. Furthermore, we analyzed whether and by how much the news affected acceptance of the vaccination.

Methods

This study was conducted as a part of Osaka Clinical resEArch of HPV vacciNe (OCEAN) study. A questionnaire was distributed to 2,777 study registrants.

Results

The response rate was 38 %. The recognition rate of the news of the vaccine’s adverse events was 80 %; it was 68 % for awareness of the government’s announcement of the suspension of its recommendation for the vaccine. Among those who had a chance to hear or see the negative news during their vaccination period, 46 (60 %) continued vaccination while knowing of the news, 22 (29 %) discontinued vaccination, and 9 (11 %) continued vaccination without an awareness of the news. Reports of the vaccine’s adverse events were the main reason for not continuing the vaccination series. Those who consulted doctors after hearing the adverse news were significantly more likely to continue their vaccinations than those who did not.

Conclusions

Our results should help in understanding the need for a strong promotion of vaccine usage and cancer screening after future retraction of the recommendation suspension. This may apply to other countries with an unsatisfactory rate of HPV vaccination due to fears of adverse vaccine events.
Literature
1.
2.
3.
Munoz N, Bosch FX, Castellsague X et al (2004) Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111:278–285PubMedCrossRef
4.
Smith JS, Lindsay L, Hoots B et al (2007) Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121:621–632PubMedCrossRef
5.
Li N, Franceschi S, Howell-Jones R et al (2011) Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer 128:927–935PubMedCrossRef
6.
Miura S, Matsumoto K, Oki A et al (2006) Do we need a different strategy for HPV screening and vaccination in East Asia? Int J Cancer 119:2713–2715PubMedCrossRef
7.
Jacobs MV, Walboomers JM, Snijders PJ et al (2000) Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer 87:221–227PubMedCrossRef
8.
Clifford GM, Gallus S, Herrero R et al (2005) Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 366:991–998PubMedCrossRef
9.
Franceschi S, Herrero R, Clifford GM et al (2006) Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 119:2677–2684PubMedCrossRef
10.
de Sanjose S, Quint WG, Alemany L et al (2010) Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 11:1048–1056PubMedCrossRef
11.
Onuki M, Matsumoto K, Satoh T et al (2009) Human papillomavirus infections among Japanese women: age-related prevalence and type-specific risk for cervical cancer. Cancer Sci 100:1312–1316PubMedCrossRef
12.
13.
14.
15.
Darden PM, Thompson DM, Roberts JR et al (2013) Reasons for not vaccinating adolescents: national immunization survey of teens, 2008–2010. Pediatrics 131:645–651PubMedCrossRef
16.
Wong MC, Lee A, Ngai KL et al (2013) Knowledge, attitude, practice and barriers on vaccination against human papillomavirus infection: a cross-sectional study among primary care physicians in Hong Kong. PLoS One 8:e71827PubMedCentralPubMedCrossRef
17.
Sotiriadis A, Dagklis T, Siamanta V et al (2012) Increasing fear of adverse effects drops intention to vaccinate after the introduction of prophylactic HPV vaccine. Arch Gynecol Obstet 285:1719–1724PubMedCrossRef
18.
Bodemer N, Muller SM, Okan Y et al (2012) Do the media provide transparent health information? A cross-cultural comparison of public information about the HPV vaccine. Vaccine 30:3747–3756PubMedCrossRef
19.
Holman DM, Benard V, Roland KB et al (2014) Barriers to human papillomavirus vaccination among US adolescents: a systematic review of the literature. JAMA Pediatr 168:76–82PubMedCrossRef
20.
Kessels SJ, Marshall HS, Watson M et al (2012) Factors associated with HPV vaccine uptake in teenage girls: a systematic review. Vaccine 30:3546–3556PubMedCrossRef
21.
Hanley SJ, Yoshioka E, Ito Y et al (2012) Acceptance of and attitudes towards human papillomavirus vaccination in Japanese mothers of adolescent girls. Vaccine 30:5740–5747PubMedCrossRef
22.
Dinh TA, Rosenthal SL, Doan ED et al (2007) Attitudes of mothers in Da Nang, Vietnam toward a human papillomavirus vaccine. J Adolesc Health 40:559–563PubMedCrossRef
23.
Dempsey AF, Abraham LM, Dalton V et al (2009) Understanding the reasons why mothers do or do not have their adolescent daughters vaccinated against human papillomavirus. Ann Epidemiol 19:531–538PubMedCentralPubMedCrossRef
24.
25.
Daley MF, Crane LA, Markowitz LE et al (2010) Human papillomavirus vaccination practices: a survey of US physicians 18 months after licensure. Pediatrics 126:425–433PubMedCrossRef
26.
Chow SN, Soon R, Park JS et al (2010) Knowledge, attitudes, and communication around human papillomavirus (HPV) vaccination amongst urban Asian mothers and physicians. Vaccine 28:3809–3817PubMedCrossRef
27.
Metadata
Title
Effect on HPV vaccination in Japan resulting from news report of adverse events and suspension of governmental recommendation for HPV vaccination
Authors
Akiko Morimoto
Yutaka Ueda
Tomomi Egawa-Takata
Asami Yagi
Yoshito Terai
Masahide Ohmichi
Tomoyuki Ichimura
Toshiyuki Sumi
Hiromi Murata
Hideharu Kanzaki
Hidekatsu Nakai
Masaki Mandai
Kiyoshi Yoshino
Masami Fujita
Tadashi Kimura
Junko Saito
Tomotaka Sobue
Nobumichi Nishikawa
Masayuki Sekine
Takayuki Enomoto
Yorihiko Horikoshi
Tetsu Takagi
Publication date
01-06-2015
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 3/2015
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-014-0723-1

Other articles of this Issue 3/2015

International Journal of Clinical Oncology 3/2015 Go to the issue

Original Article

4-step 4-h carboplatin desensitization protocol for patients with gynecological malignancies showing platinum hypersensitivity: a retrospective study

Review Article

Molecular pathogenesis of multiple myeloma

Original Article

A phase I study of combination therapy with nanoparticle albumin-bound paclitaxel and cyclophosphamide in patients with metastatic or recurrent breast cancer

Original Article

Effects of chemotherapy on patients with recurrent cervical cancer previously treated with concurrent chemoradiotherapy: a retrospective multicenter survey in Japan

Original Article

Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results

Original Article

Comparison of therapeutic results from radiofrequency ablation and stereotactic body radiotherapy in solitary lung tumors measuring 5 cm or smaller
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits